Showing results (561-570 of 655) with videos related to
Sort By:
Pageof 66
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 6, 2024
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®)Minji K Lee, Sandra A Mitchell, Ethan Basch, et al.JCO Oncology Practice|August 19, 2025
Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer MeasureYashasvini Sampathkumar, Corrine I Voils, Gina L Mazza, et al.Clinical Trials (London, England)|December 1, 2020
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Claus Becker, Lauren J Rogak, et al.International Journal of Radiation Oncology, Biology, Physics|May 3, 2017
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical TrialEthan Basch, Stephanie L Pugh, Amylou C Dueck, et al.European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.Journal of the National Cancer Institute|October 1, 2014
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)Ethan Basch, Bryce B Reeve, Sandra A Mitchell, et al.JAMA Oncology|December 12, 2024
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical TrialAnn H Partridge, Terry Hyslop, Shoshana M Rosenberg, et al.JCO Oncology Practice|February 20, 2020
Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer CentersAngela M Stover, Benjamin Y Urick, Allison M Deal, et al.Nature Medicine|February 7, 2025
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trialEthan Basch, Deborah Schrag, Jennifer Jansen, et al.Pageof 66